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Abstract  
The human immunodeficiency virus type 1 (HIV-1) coreceptor use and viral 
evolution  were  analyzed  in  blood  samples  from  an  HIV-1  infected  patient 
undergoing allogeneic stem cell transplantation (SCT). Coreceptor use was 
predicted in silico from sequence data obtained from the third variable loop 
region of the viral envelope gene with two software tools. Viral diversity and 
evolution  was  evaluated  on  the  same  samples  by  Bayesian  inference  and 
maximum likelihood methods. In addition, phenotypic analysis was done by 
comparison  of  viral  growth  in  peripheral  blood  mononuclear  cells  and  in  a 
CCR5  (R5)-deficient  T-cell  line  which  was  controlled  by  a  reporter  assay 
confirming  viral  tropism.  In  silico  coreceptor  predictions  did  not  match 
experimental determinations that showed a consistent R5 tropism. Anti-HIV 
directed  antibodies  could  be  detected  before  and  after  the  SCT.  These 
preexisting antibodies did not prevent viral rebound after the interruption of 
antiretroviral  therapy  during  the  SCT.  Eventually,  transplantation  and 
readministration  of  anti-retroviral  drugs  lead  to  sustained  increase  in  CD4 
counts and decreased viral load to undetectable levels. Unexpectedly, viral 
diversity decreased after successful SCT. Our data evidence that only R5-
tropic  virus  was  found  in  the  patient  before  and  after  transplantation. 
Therefore,  blocking  CCR5  receptor  during  stem  cell  transplantation  might 
have had beneficial effects and this might apply to more patients undergoing 
allogeneic stem cell transplantation. Furthermore, we revealed a scenario of 
HIV-1 dynamic different from the commonly described ones. Analysis of viral 
evolution  shows  the  decrease  of  viral  diversity  even  during  episodes  with 
bursts in viral load.    - 3 - 
Background  
Allogeneic stem cell transplantation is frequently used to treat hematologic 
neoplasms and is a feasible treatment option for patients also infected with 
human immunodeficiency virus (HIV). Infection of the target cell with HIV-1 
requires the presence of the CD4 receptor and a chemokine receptor, mostly 
either CCR5 (R5) or CXCR4 (X4). Primary HIV-1 infection usually arises from 
R5-tropic HIV strains. In around 50% of the patients infected with a HIV-1 
subtype B virus, a switch in viral co-receptor usage from R5 to X4 can be 
observed  and  the  presence  of  X4-tropic  HIV  is  usually  accompanied  by  a 
faster  disease  progression  [1].  The  cause  of  the  coreceptor  switch  is  still 
unknown,  but  it  can  be  regarded  as  a  side-effect  of  selective  sweeps  in 
response to evolutionary pressures imposed by the immune response and/or 
by  anti-retroviral  therapy  (ART).  Within-patient  HIV  evolution  is  a  complex 
process that is influenced by a multitude of host-, virus- or therapy-specific 
factors and usually proceeds towards increased diversity of viral isolates with 
time  [2]. Therefore  we  were  interested  in analyzing  the  HIV-1  evolutionary 
dynamics in samples isolated diachronically from a HIV-infected patient with 
severe  aplastic  anemia  who  underwent  stem  cell  transplantation  and  was 
further monitored for 384 days. The viral-host interaction in this patient can be 
thus considered as occurring after a partial restart of the adaptive immune 
response due to the stem cell transplantation thereby resembling a primary 
HIV infection.  
 
Methods 
Stem cell transplantation 
The 34 year-old HIV-infected male had been diagnosed with an HIV-infection 
in 2001 and with severe aplastic anemia in 2005. The patient had regularly 
followed  highly  active  antiretroviral  therapy  (HAART)  for  50  months  before 
transplantation and was treated with an allogeneic stem cell transplant of a 
10/10 alleles HLA-matched. HAART was discontinued on day 0 until day 34 to 
avoid  potential  drug  interactions.  The  conditioning  regimen  included   - 4 - 
fludarabine  and  cyclophosphamide  [3].  Blood  samples  were  supplied 
anonymously by TW who obtained written informed consent from the patient 
for publication of this case report. 
 
Sequence analysis of Env V3 region 
Either chromosomal DNA from peripheral blood mononuclear cells (PBMCs) 
or  viral  RNA  was  used  as  template.  RNA  was  prepared  from  the  cell-free 
supernatant of infected cell cultures using QIAamp viral RNA kit (Quiagen, 
Hilden,  Germany)  and  reverse  transcribed  using  the  First  strand  cDNA 
Synthesis  Kit  (Amersham  Biosciences,  UK).  PCR  amplification  of  the  V3 
region was performed as previously described [4]. Amplification products were 
directly ligated into the pGEMT vector (Promega, Mannheim, Germany) and 
nucleotide  sequencing  was  performed  using  dye-labeled  terminators 
(Eurofins/MWG/operon; Ebersberg, Germany). For each sample ten separate 
sequences were determined and can be obtained on request. 
  
Phenotypic determination of coreceptor usage  
Virus-containing supernatants were serially diluted in media and aliquoted (50 
µL  per  well,  three  replicates  per  dilution)  into  U-well  microtiter  plates 
containing  2  x  10
5  of  IsnoR5  cells  or 4.5 x  10
5  PBMC from  healthy  blood 
donors in 150 µL medium. After 14 days of incubation at 37
oC, cultures were 
centrifuged  and  cell-free  supernatants  were  inactivated  by  the  addition  of 
Tween  20  to  a  final  concentration  of  0.2%.  25  µL  of  each  sample  was 
transferred to the corresponding well of an ELISA plate for detection of viral 
Gag protein using a p24 antigen capture assay [4]. 
TZM-bl  cells  were
  obtained  from  the  NIH  AIDS  Research  and
  Reference 
Reagent Program (No. 8129). This is a genetically engineered HeLa cell clone
 
that expresses CD4, CXCR4, and CCR5 and contains Tat-responsive
 reporter 
genes  for  firefly  luciferase  and  Escherichia  coli  ß-galactosidase
  under 
regulatory control of an HIV-1 long terminal repeat. 1x10
6 TZM-bl cells were 
seeded in 6 well- plates (Sarstedt) in presence or absence of 1.5 µM Vicrivroc 
(Selleck). One day after plating media was renewed and cells were infected   - 5 - 
with the different HIV isolates. Infection of TZM-bl cells was assessed
 2 days 
after infection by fixing in cold 2% paraformaldehyde
 in PBS. Afterwards cells 
were stained for one hour at 37° C by adding 5-bromo-4-chloro-3-indolyl-ß-
galactopyranoside
 (X-Gal) substrate (Roth) at 0.5 mg/ml
 in PBS containing 4 
mM potassium ferrocyanide, 4 mM potassium
 ferricyanide, 2 mM magnesium 
chloride. Blue-stained cells/syncytia were counted. 
 
Humoral immune responses 
The  presence  of  antibodies  directed  against  HIV-1  or  HIV-2  antigens  in 
plasma samples of the patient were detected with MP Diagnostics HIV BLOT 
Version 2.2 Western Blots (Illkirch, France)) following the description of the 
manufacturer. 
 
In silico coreceptor prediction 
The  coreceptor  prediction  was  done  either  with  the  WebPSSM 
(http://indra.mullins.microbiol.washington.edu/pssm/)  [5]  or  the  geno2pheno 
(http://coreceptor.bioinf.mpi-inf.mpg.de/index.php)  [6]  software  tools  [7]. 
WebPSSM is a bioinformatic tool for predicting HIV-1 coreceptor use from the 
amino acid sequence of the V3 loop of the envelope gene in subtype B and 
subtype C HIV. Sequences are aligned against a consensus sequence and 
their amino acid composition is evaluated on the basis of a position specific 
scoring  matrix  (PSSM)  which  contains  information  about  the  amino  acid 
composition of the V3 loop in R5 and X4 viruses. A positive score indicates 
X4 tropism while negative values can predict X4 virus with high uncertainty 
only. 
Geno2pheno is based on a statistical learning method called a support vector 
machine (SVM). The program is only trained to detect CXCR4 use, in which 
X4 and R5X4 viruses are taken as belonging to the X4 class. All predictions 
were done applying the default FPR of 10%. 
 
Phylogenetic analysis 
V3  sequences  were  aligned  at  the  amino  acid  level  with  MUSCLE  and 
corrected  by  hand.  Bayesian  phylogenetic  analysis  was  performed  at  the   - 6 - 
nucleotide  level  with  BEAST  v1.4.8  (http://beast.bio.ed.ac.uk)  [8]  using  the 
GTR+Γ4 model of evolution for both strict clock and uncorrelated log normal 
relaxed clock, introducing three partitions that corresponded to each of the 
codon  positions,  and  unlinking  parameters  across  codon  positions. 
Exploratory runs were performed with 50 million steps, writing every 1,000 
steps, both for the relaxed and strict clock and compared by calculating the 
Bayes factor on the corresponding likelihoods. There was better support for 
the relaxed clock calculations (log Bayes factor=24.2±0.44). A chain of 100 
million steps was therefore calculated for a relaxed clock model, writing every 
1,000  steps  (later  reduced  to  every  2,000  steps  for  further  analysis),  and 
analyzed with a burn-in of ten million steps. Effective viral population sizes 
were calculated using the time-labeled sequences gained from the patient, as 
a “Bayesian skyline” [9]. Maximum Likelihood (ML) phylogenetic analysis was 
performed with RAxML HPC [10], [11] using the GTR+Γ4 model of evolution 
and  the  CAT  approximation  of  rate  heterogeneity  [10],  introducing  three 
partitions  that  corresponded  to  each  of  the  codon  positions.  Pair-wise 
distances between sequences collected at the same day were calculated with 
the same ML parameters using the best ML tree. 
 
Case presentation  
The  34  year-old  HIV-infected  male  was  diagnosed  with  severe  aplastic 
anemia  in  2005.  The  patient  was  treated  with  an  allogeneic  stem  cell 
transplant and HAART was discontinued on day 0 until day 34. As indicated in 
figure  1,  HIV  viral  load  rapidly  rose  from  undetectable  levels  to  6.8  x  10
6 
copies/mL after transplantation and antiretroviral therapy was reintroduced at 
day 34, resulting in a prompt 4-log reduction of the viral load, and gradually 
normalizing CD4 counts. A 99% donor chimerism was determined from bone 
marrow samples and the patient is in CDC-stage A2 now. A progression of his 
HIV infection could not be noted throughout the procedure [3].   
 
Genotyping of HIV-1 coreceptor use   - 7 - 
The genotypic coreceptor prediction was done by sequence analysis of the 
third variable loop (V3) region of the viral envelope (env) gene, which is the 
primary  determinant  of  coreceptor  use.  Env  sequences  were  derived  of 
cellular  genomic  DNA  (except  for  sample  at  day  198  after  transplantation, 
where cDNA from viral supernatants was isolated) isolated from the patient at 
different time points as indicated in figure 2 with the date of SCT as reference 
day 0. Two different algorithms were used for in silico coreceptor prediction: 
WebPSSM  [5]  and  geno2pheno  [7].  All  env  sequences  were  classified  as 
subtype B HIV-1 by the geno2pheno tool. 
 
WebPSSM predicted CXCR4 use except for one sample obtained from the 
patient. However the negative score of the prediction implied a high degree of 
uncertainty (figure 2). Geno2pheno predicted for all samples X4 use (figure 2, 
left).  
 
In addition to the V3 region, sequence changes within the V1, V2 and C4 
regions of the envelope protein have also been shown to have a profound 
impact on  coreceptor  use  (reviewed  in  [12])  and  coreceptor  predictions  by 
bioinformatic  tools  still  encounter  limitations  as  R5  and  X4  viruses  are not 
trivially separable on the basis of their V3 loop amino acid sequence [13], [14]. 
Therefore we characterized the patient-derived HIV-1 isolates for coreceptor 
tropism with two cell-based assays. Patient-derived viruses were amplified by 
one passage in PBMCs of an unrelated donor and for three samples sufficient 
amounts  of  virus  could  be  obtained  for  testing.  The  coreceptor  use  was 
determined by comparison of viral growth in the recently established CCR5-
deficient CD4-positive T cell line, IsnoR5 and PBMCs in triplicates [4]. Viral 
replication in IsnoR5 cells indicates X4 or alternative receptor use, whereas 
absence of replication in IsnoR5 cells reveals R5 use. The viruses were able 
to  replicate  in  PBMCs  but  not  in  IsnoR5  cells  indicating  R5  use  (figure  2, 
columns 4 and 5). To verify these results, we used TZM-bl cells, which are a 
genetically  engineered  HeLa  cell  clone
  that  expresses  CD4,  CXCR4,  and 
CCR5  and  contains  a  Tat-responsive
  ß-galactosidase
  gene  and  allows  for 
monitoring of HIV-1 infection by staining the cells for ß-galactosidase activity. 
In addition, we analyzed infection of TZM-bl cells in the presence of Vicrivroc,   - 8 - 
a  specific  CCR5  inhibitor.  TZM-bl  cells  could  be  infected  with  the  patient-
derived virus, but infection was inhibited in the presence of Vicrivroc (R5i), 
demonstrating R5 use. For control, we used the typical R5-tropic HIV-1 SF162 
and  infection  of TZM-bl  cells  was  also  diminished  by  Vicrivroc,  whereas  a 
typical X4 virus (SF2) was not significantly affected (figure 2 columns 6 and 
7).  
The  data  clearly  show  that  in  contrast  to  the  in  silico  predictions  virions 
isolated  from  the  patient  both  before  and  after  the  SCT  use  the  CCR5 
receptor for entry.  
 
Humoral immune response 
The  immunoblot  analysis  of  HIV  antigens  revealed  the  presence  of  HIV-1 
specific antibodies throughout days -92 to +384 after stem cell transplantation. 
The patient had antibodies reactive towards HIV-1 proteins and was HIV-2 
negative (figure 3). 
 
Intrapatient HIV evolution  
The  here  described  SCT  can  be  considered  as  a  treatment  interruption  in 
combination  with  an  extensive  depletion  of  the  cellular  immune  response 
which resulted in a strong viral rebound. Still, HIV specific antibodies remain 
prevalent in the patient and CD4 cell counts stabilize with the control of viral 
load after re-initiation of HAART. To analyze viral dynamics in this specific 
setting, we have studied viral diversity and phylogeny by means of ML and 
Bayesian  methods.  We  have  reconstructed  the  phylogeny  of  HIV  in  the 
patient  assuming  viral  evolution  following  a  general  time-reversible  model 
allowing  for  heterogeneity  in  substitution  rates  among  codon  positions  and 
sites and incorporating an uncorrelated relaxed clock for the branch rates. In a 
Bayesian  MCMC  framework  implemented  in  the  software  Beast,  these 
parameters  and  associated  tree  topologies  are  sampled  and  optimized  to 
maximize  posterior  probabilities  given  the  evidence  of  sequence  samples 
taken from the patient (d-61, d-8, d20, d35, d42, d105, d120, d198, d384 after 
transplantation).  Time-labeled  sequences  are  used  to  estimate  diachronic 
changes in effective viral population sizes from its posterior distribution. This   - 9 - 
so called skyline plot is a proxy for the diversity of the viral population over 
time [9].  
Additionally, pair-wise distances based on ML analyses were calculated for 
the sequences gathered at each time point. A summary of this analysis can 
be found in figure 4.  
Interruption of HAART before SCT treatment results in a burst in viral load 
(figure 1, inset). However, we could not observe an increase in viral diversity 
or the emergence of a multitude of strains from reservoirs as a consequence 
of  strong  viral  replication  at  the  release  of  viral  control.  To  the  contrary, 
phylogenetic  analysis  showed  that  viral  diversity  decreased  after  SCT  and 
remained at low levels thereafter. This can be seen qualitatively in the shape 
of the tree (figure 4A) that is reduced to a backbone of one branch after SCT 
and more quantitatively in the associated skyline plot (figure 4B) in which the 
effective  population  size  shrinks  to  a  few  sequences  indicating  minimal 
diversity  and  in  the  decreasing  values  for  pair-wise  distances  among 
contemporaneous sequences (figure 4C). 
 
Discussion  
One of the unsolved mysteries of HIV-1 infection is the observation that most 
HIV-1 transmissions result in a R5 virus infection. Only with time, X4 variants 
arise  in  approximately  50%  of  infected  individuals  and  their  appearance 
correlates  with  unfavourable  clinical  outcome  [1].  We  described  here  the 
analysis of the viral rebound of a HIV-infected patient after discontinuation of 
HAART  as  a  result  of  bone  marrow  transplantation.  Although  genotypic 
analyses predicted the presence X4-tropic viruses in the patient, phenotypic 
coreceptor  determination  revealed  only  the  presence  of  R5-tropic  viruses 
before and after SCT including one sample taken during the viral rebound. 
The discrepancy between geno- and phenotyping is most likely due to the fact 
that the positions 9-10 of the V3 loop, unusually encode for the amino acids 
arginine and lysine (RK) or lysine and lysine (KK), however the sequences of 
the patient had an asparagine and lysine (NK) at this position, which could 
hamper  the  predictions  [7].  Phenotypic  coreceptor  determination  using   - 10 - 
IsnoR5 cells is highly sensitive and is able to detect minor amounts of X4-
tropic HIV, suggesting that no X4 viruses were present in the patient [4]. This 
is reminiscent to the recently described stem cell transplantation with donor 
cells  homozygous  for  CCR5delta32  [15].  In  this  case,  putative  minor 
populations of X4-tropic HIV did not cause a re-infection of the patient even 
two years after transplantation. This indicates that new infection of the donor 
lymphocytes  is  either  limited  to  R5-tropic  strains  or  replication  of  the  less 
abundant  X4-tropic  strains  has  not  yet  been  detected  [15].  In  addition, 
structured treatment interruption (STI) of chronically HIV-1 infected patients 
has been described to lead to a rapid re-emergence of HIV from reservoirs 
and  to  a  dominance  of  R5-  over  X4-using  strains  in  patients  [16].  This 
suggests  that  R5-tropic  strains  have  a  selection  advantage  after  stem  cell 
transplantation and STI and that the preferred infection via R5 is independent 
of the way of entry into the body. This implies that CCR5 inhibitors might be 
beneficial  during  the  transplantation  procedure.  In  addition,  stem  cell  gene 
modification, inactivating CCR5 receptor expression, might be considered to 
be useful, too. 
 
The  patient  described  here  had  successfully  undergone  stem  cell 
transplantation and showed a 99% chimerism, which should have eliminated 
most preexisting HIV-specific effector T cells. Despite the strong decrease in 
CD4  counts,  HIV-specific  antibodies  were  present  during  stem  cell 
transplantation,  which  might  be  caused  by  long-lived  plasma  cells  that 
survived the conditioning and the immunosuppressive treatments. The data 
suggest  that  the  high  prevalence  of  HIV-specific  antibodies  during  viral 
rebound was unable to prevent rapid HIV replication, but we cannot exclude 
that they contributed to restrict viral evolution.  
 
The  viral  envelope  protein  is  exposed  to  the  surface  and  is  subject  to 
selection pressure by the immune system and the rate of evolution of this 
gene  is  approximately  1%  per  year  [17].  Both  the  immune  system  and 
antiretroviral therapy impose a selection pressure on the virus towards the 
emergence  of  resistant  viral  strains  that  usually  decrease  viral  replicative 
fitness.  Thus,  viral  strains  can  re-emerge  from  hidden  viral  reservoirs  in   - 11 - 
patients  as  soon  as  therapy-  or  immune  response-mediated  selective 
pressures  are  released  [18].  This  has  especially  been  investigated  for  STI 
which  mostly  leads  to  a  viral  rebound  associated  to  the  re-emergence  of 
strains and the development of resistances and often linked to a decline in 
CD4 cell counts [16,19,20]. Surprisingly, the typical pattern of increased viral 
load and increased viral diversity found in STI does not occur in our case. 
While HAART interruption does result in a viral rebound, there is no increased 
diversity  of  viral  strains  that  might  be  released  from  the  patient’s  hidden 
reservoirs. This indicates that the, at least partial knock-out of the immune 
system and the establishment of a new immune system imposes a selection 
pressure different from those generated by STI.  
 
One might hypothesize that viral load is controlled by therapeutic measures 
before the patient’s immune system is again operational after SCT. Therefore 
no  specific  immune  response  could  be  newly  established  shifting  the 
relevance  of  evolutionary  pressures  towards  the  less  strain  specific 
therapeutic  measures.  This  might  decrease  the  selection  pressure  for 
diversity in the viral quasispecies [21,22]. However, this does not resolve the 
puzzle why HIV shows less diversity in this patient after SCT and STI than 
under STI alone. It would be anticipated instead that the additional depletion 
of the cellular immune system should worsen the ambivalent prognosis after 
STI.  Maybe  elimination  of  hidden  HIV-1  reservoirs  before  SCT  suffices  to 
reduce  the  potential  to  generate  viral  diversity  from  dormant  sequences, 
implying that viral diversity arising de novo through viral evolution is limited.  
 
Conclusion 
In  summary,  our  data  from  this  case  report  of  an  HIV-1-infected  patient 
undergoing SCT evidence that only R5-tropic virus was found in the patient 
before and after transplantation. In addition, the presence of HIV-1-specific 
antibodies  was  found  in  all  plasma  samples  over  time.  Remarkably,  the 
patient  experienced  an  HIV-1  dynamic  scenario  different  from  commonly 
described ones. Detailed analysis of viral evolution shows the decrease of   - 12 - 
viral  diversity  even  during  episodes  with  bursts  of  viral  load  in  contrast  to 
observations under STI.  
Given that SCT has become a more frequent treatment option for HIV infected 
patients,  it  will  be  important  to  investigate  in  future  studies  whether  our 
observations  of  only  one  patient  are  rather  anecdotal  evidence  or  point 
instead towards an important mechanism of HIV evolution. In addition, our 
findings  might  have  implications  for  vaccine  development,  which  is  mainly 
hampered by the great diversity of HIV. 
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Figure legends 
 
Figure 1 
Viral load and CD4 counts in the stem cell transplanted patient.  
The gray bars indicate the duration of ART, which was discontinued at day 0 
for allogenic SCT and was restarted at day 34, the inset shows the first 100 
days after allo-SCT. Additional sequence samples for phylogenetic analysis 
were taken at time points marked by arrows. CD4 counts are given in gray 
and viral load in black. 
 
Figure 2 
Summary  of  genotypic  coreceptor  predictions  and  phenotypic  coreceptor 
determinations. 
The  HIV-1  env  C2V5  sequence  was  amplified from  genomic  DNA  isolated 
from patient derived PBMCs at the indicated time points as described before 
[4].  Coreceptor  usage  was  predicted  either  with  WebPSSM  (score  of 
sequences shown) or geno2pheno. Patient derived HIV-1 was amplified once 
on  donor  PBMCs  and  was  used  to  infect  PBMCs  or  IsnoR5  cells.  Viral 
replication  in  the  analyzed  cells  was  determined  by  p24  Elisa  [4]  and  is 
indicated as + or -. In a second confirmatory assay, patient-derived virus or 
lab strains were used to infect TZM-bl cells or TZM-bl cells in the presence of 
Vicrivroc  (R5i)  and  infection  was  monitored  by  lacZ  staining.  Positive  cells 
were  counted  and  the  numbers  are  indicated.  The  last  column  gives  the 
coreceptor use deduced from in vitro phenotyping. N.d. = not done. 
 
Figure 3 
Humoral immunity. 
HIV-1-specific  antibodies  were  detected  by  Western  blot  analysis  (MP 
Diagnostics  HIV  BLOT  Version  2.2  Western  Blots  (Illkirch,  France))  from 
plasma samples at the indicated time points. The major HIV-1 proteins are 
indicated by arrows and negative, positive and week positive control samples 
were included. 
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Figure 4 
Viral evolution. 
A)  Bayesian  evolutionary  chronogram  for  the  time-labelled  viral  sequences 
sampled  at  the  indicated  dates.  Note  that  the  evolutionary  tree  evolves 
towards simplification and finishes simply as a backbone of a single branch.  
B)  Viral  effective  population  sizes  as  inferred  after  Bayesian  skyline 
calculation; median value is shown in continuous line; dotted lines represent 
the  95%  highest  posterior  density  (HPD)  interval  around  the  median.  Viral 
diversity decreases with time and plateaus after SCT.  
C) Pair-wise distances among sequences sampled at the corresponding 
dates, as inferred after maximum likelihood criterion using the GTR+Γ4 
model. F
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